Most melanoma cells are characterized by the V600E mutation in B-Raf kinase. This mutation leads to increased expression of interleukin (CXCL8), which plays a key role in cell growth and angiogenesis. Thus CXCL8 appears to be an interesting therapeutic target. Hence, we performed vaccination of mice with GST-CXCL8, which results in a reduced incidence of syngenic B16 melanoma cell xenograft tumors. We next addressed the molecular mechanisms responsible for aberrant CXCL8 expression in melanoma. The CXCL8 mRNA contains multiples AU-rich sequences (AREs) that modulate mRNA stability through the binding of tristetraprolin (TTP). Melanoma cell lines express very low TTP levels. We therefore hypothesized that the very low endogenous levels of TTP present in different melanoma cell lines might be responsible for the relative stability of CXCL8 mRNAs. We show that TTP is actively degraded by the proteasome and that extracellularregulated kinase inhibition results in TTP accumulation. Conditional expression of TTP in A375 melanoma cells leads to CXCL8 mRNA destabilization via its 3= untranslated regions (3=-UTR), and TTP overexpression reduces its production. In contrast, downregulation of TTP by short hairpin RNA results in upregulation of CXCL8 mRNA. Maintaining high TTP levels in melanoma cells decreases cell proliferation and autophagy and induces apoptosis. Sorafenib, a therapeutic agent targeting Raf kinases, decreases CXCL8 expression in melanoma cells through reexpression of TTP. We conclude that loss of TTP represents a key event in the establishment of melanomas through constitutive expression of CXCL8, which constitutes a potent therapeutic target.
the G protein-coupled receptors CXCR1 and CXCR2, but most of the angiogenic properties depend on CXCR2 (51) . Melanoma cells strongly express CXCL8 mRNA and secrete the protein (6) . In contrast to neutrophils, CXCR2 is the major CXCL8 receptor in melanoma (40) . CXCL8 has been implicated in melanoma progression through the promotion of cell growth and migration and has been considered in vitro as a mitogen, since antisense oligonucleotides or neutralizing CXCL8 antibodies decreased melanoma cell proliferation in culture (16) . CXCL8 induces matrix metalloproteinase-2 expression facilitating extracellular matrix degradation and migration. Hence, CXCL8 appears to be a major chemokine implicated in the development of melanoma. Determining how CXCL8 is regulated constitutes a challenge in highlighting potential therapeutic targets, prognostic markers of tumor aggressiveness, or markers of treatment failure. Most of the melanoma cells are characterized by the somatic V600E mutation of the B-Raf kinase, which leads to constitutive activation of the mitogen-activated protein kinase kinase (MEK)/ extracellular-regulated kinase (ERK) pathway (11) . Such activation is a key event for induction of VEGF and CXCL8 gene transcription (53) . However, constitutive ERK activity also regulates mRNA stability providing sustained RNA levels for translation (13) . Hence, we hypothesized that the regulatory proteins implicated in downregulation of these cytokines might be downregulated or inhibited through constitutive activation of ERK. Tristetraprolin (TTP) might be a good candidate since it downregulates the half-life of many inflammatory and angiogenic cytokines including CXCL8 (3, 47) and VEGF (13) . TTP exerts its action by binding to cis-acting elements that are adenylate and uridylate-rich elements (AREs) (25) , and it acts as a potent tumor suppressor when overexpressed in a v-HRas-dependent mast cell tumor model (45). The TTP protein is multiphosphorylated by mainly p38 and to a lesser extent by ERK and mitogen-activated protein (MAP) kinases (8) , and phosphorylation affects its expression and activity (13, 19) . The goal of our study was to analyze the incidence of TTP expression in melanoma and to determine whether modulation of its expression could influence melanoma development through expression of CXCL8, a potent autocrine growth factor and a potent angiogenic factor (53) .
MATERIALS AND METHODS
Plasmid constructs. The pCDNA4/TO/mycTTP vector has already been described (13) . The following oligonucleotides were used to amplify the region corresponding to the CXCL8 3= untranslated regions (3=-UTR) from human genomic DNA: forward oligo: 5=-CTGCAGCATTCTCTGTGGTATCCAAG-3=; reverse oligo: 5=-TCTAGACAAAGAGAATCCCAATAAGC-3=. The amplified fragment was inserted into pCR2.1 TOPO (Invitrogen, Cergy Pontoise, France). This vector was cut with EcoRI, and the fragment was inserted into the Bluescript SKϩ vector. A HindIII fragment from an already used TK luciferase vector was inserted into the Bluescript/ CXCL8 3=-UTR vector to obtain the TK luciferase/CXCL8 3=-UTR vector. The CXCL8 cDNA was amplified by PCR with the following oligonucleotides: forward primer 5=-CGGGATCCAGTGCTAAA-GAACTTAGATGTCAG-3=; reverse primer; 5=-CTCGAGTTAT-GAATTCTCAGCCCTCTTC-3=. The amplified fragment was inserted into BamHI and XhoI sites of the pGEX 6P1 vector (GE Healthcare, Chalfont, St. Giles, UK). The GST-CXCL8 fusion protein was produced to immunize mice. The reporter vector for the IL-8 promoter was a kind gift of Dr. Bar-Sagi (44) .
Antibodies and reagents. The anti-TTP and anti-LC3 antibodies were homemade (4, 13) . The BNIP3 antibody was from SigmaAldrich (L'Isle d'Abeau, Chesnes, France). Anti-phospho ERKs were from Sigma-Aldrich, and anti-ERK and anti-HSP90 were from Santa Cruz Biotechnology (Santa Cruz, CA), horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies were from Promega (Madison, WI). The anti-CXCL8 antibodies were from R&D systems (Lille, France). PD184352 and MG132 were from Calbiochem (Nottingham, UK) and were used at a concentration of 5 and 10 M, respectively. Control short hairpin RNA (shRNA) and shRNA targeting TTP were from Sigma-Aldrich. Treatments of cell extracts with calf intestine phosphatase were performed as previously described (30) .
RNA preparation and analysis by quantitative PCR. Total RNA was extracted with TRIzol Reagent (Invitrogen). Two micrograms of total RNA were used for reverse transcription, using the Superscript First-Strand Synthesis System (QIAGEN, Hilden, Germany) with oligo(dT) to prime first-strand synthesis. For real-time PCR, The Taqman Gene expression assay (Applied Biosystems, Courtaboeuf, France) and qPCR core kit (Eurogentec, Liege, Belgium) were used. Reactions included 40 cycles at 94°C for 30 s and 60°C for 1 min. To calculate the relative expression of CXCL8 and BNIP3 mRNA, the 2[ddC(T)] method was used (42) , and normalization was carried out with RPLP0. The CXCL8 mRNA half-life was calculated as previously described (13) .
Cell culture, transfection, and luciferase assay. Melanoma cell lines (A375, Mel-501, WM9, SK Mel-28, a kind gift of Dr. Corinne Bertolotto) and RAW264.7 cells (a kind gift of Dr. Matthieu Rouleau) were from the American Type Culture Collection.They were grown as previously described (26, 29) . Rosi cells were a kind gift of Dr. L. Larue (34) . They are wild type for B-Raf and N-RAS. CXCR2 expressing cells were a kind gift of Dr. R. Richardson (35) . Melanocytes and primary melanoma cells were cultivated as previously described (5) . Hypoxic conditions were induced as previously described (4). A375 cells expressing the tetracycline repressor were stably transfected either with the empty vector or pCDNA4/TO/ mycTTP and selected as previously described (13) . For proliferation assays, cells were plated in 12-well dishes at the density of 50,000 or 150,000 cells/well and allowed to grow for indicated times in standard medium. Cells exposed to the different treatments were trypsinized and counted using a Coulter counter. Silencing of TTP in A375 cells was obtained by transfecting cells with MISSION shRNA lentivirus plasmids (Sigma-Aldrich). Luciferase reporter constructs were transfected into A375 cells (Invitrogen), and the luciferase activity was measured as previously described (13) . In each case, transfection was performed with Lipofectamine 2000 (Invitrogen).
Measurement of secreted CXCL8. CXCL8 protein release was measured using an enzyme-linked immunosorbent assay (ELISA) kit (Peprotech, Neuilly-Sur-Seine, France) and normalized to cell number.
Mice immunization, detection of the presence of neutralizing antibodies, and tumor formation. Female Swiss BALB/c mice of 6 to 8 wk of age were obtained from Janvier (Le Genest, St. Isle, France).
Mice were maintained under pathogen-free conditions. Animal experiments were performed in accordance with the European ethical guidelines for animal experimentation and the United Kingdom Coordinating Committee on Cancer Research Guidelines for the Welfare of Animals in Experimental Neoplasia. All procedures involving animals were approved by the Animal Care and Use Committee, CNRS UMR 6543, France. Induction of anti-CXCL8-specific antibodies in BALB/c mice was carried out as follows. Mice were given three intraperitoneal injections 3 wk apart of either GST or GST-CXCL8 (100 g) emulsified at a 1:1 ratio in Complete Freund's Adjuvant (Sigma-Aldrich) for priming and in Incomplete Freund's Adjuvant for boosting. Before tumor cell injection, a retro-orbital blood sample was obtained for each mouse. Serum was recovered and incubated with protein-G-Sepharose beads in TNE buffer (consisting of Tris 10 mM, NaCl 100 mM, and EDTA 1 mM) with 1% BSA for 16 h. CXCL8 (50 ng) (Sigma-Aldrich) was incubated in TNE with the coated beads for 3 h at 4°C. The supernatant was used to stimulate CXCR2 expressing cells for 5 min (43) . Cells were lysed in Laemmli sample buffer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Billerica, MA). ERK and phospho-ERKs were visualized by the enhanced chemiluminescence detection system (ECL; Pierce Chemical, Rockford, IL) and quantified using Image J software. B16F10 syngenic melanoma cells (10 6 cells) (14) were injected subcutaneously into the flanks of mice immunized with GST or GST/CXCL8 (10 mice per condition). Tumor incidence was calculated as the number of mice that developed a tumor divided by the total number of mice.
Statistical analysis. The results for cell count/proliferation, luciferase activity, mRNA, and protein levels are given as an average of at least three separate experiments. Results are presented as means Ϯ SD. The statistical significance of the differences between the values in the treated and control cells for proliferation tests was determined by a nonparametric Mann-Whitney U test. An unpaired, two-tailed Student's t-test was used for ELISA and mRNA level determination. Statistical differences between controls and treated cells were considered significant when P was Ͻ0.05.
RESULTS
Mice vaccination against CXCL8 reduces the incidence of melanoma. CXCL8 is a major factor implicated in the development of melanoma (37) . Although, CXCL8 does not exist in mice, CXCL5, an ELRϩ CXCL family member, is considered to be the mouse CXCL8 ortholog (52) . Moreover, CXCL8 shares common sequences with all the mouse CXCL family members starting from the ELR sequence situated after the signal peptide (see online Supplemental Fig. S1 at the AJP-Cell Physiol website). To define CXCL8 as a potential therapeutic target, BALB/c mice were immunized with GST/CXCL8 or GST alone as indicated in MATERIALS AND METHODS. CXCL8 stimulates ERK activity in CXCR2-expressing cells (35) , and commercial anti-CXCL8 antibodies prevent this activation (Fig. 1A ). Antibodies present in the sera of GST/CXCL8 immunized mice inhibit CXCL8-induced activation of ERK through stimulation of the CXCR2 receptor, whereas sera of control mice do not (Fig. 1, A and B) . The sera of GST/CXCL8 immunized mice also inhibit mouse CXCL1 and mouse CXCL5-induced activation of ERK in CXCR2-expressing cells ( Fig. 1B and online Supplemental Fig. S2 ). This result indicates that only sera of GST/CXCL8-immunized mice contain anti-CXCL8 antibodies but also anti-mouse-CXCL1 and anti-mouse-CXCL5. It is an important point since CXCL1 and CXCL5 are considered as the orthologs of CXCL8 in mice (21) . Syngenic B16F10 melanoma cells were then injected into GST and GST/CXCL8 immunized mice, and tumor growth was determined. Figure 1C clearly shows a delay in tumor appearance and an almost 50% reduction in the incidence of melanoma in the GST/CXCL8 immunized mice, suggesting that inhibition of the mouse CXCL8 orthologs (CXCL1 and CXCL5) or more generally agonists of CXCR receptors might be prophylactic against melanoma development. Two GST/ CXCL8 immunized mice (B4 and B6) developed a tumor. Their sera had the lowest capacity to reduced CXCL8 and mouse CXCL5-induced ERK activation of CXCR2 expressing cells. The serum of mouse B4 has also the lowest capacity to reduce CXCL-1-induced ERK activation (online Supplemental Fig. S2 ). B7 and B9 mice did not develop tumors suggesting that a threshold of inhibition of CXCL8 or its orthologs should be reached to prevent tumor development. These results suggest that CXCL8 or its mouse ortholog represents a major actor of melanoma development.
TTP expression in melanoma cell lines. CXCL8 appears as a key regulator of melanoma growth and metastasis (37) . Since CXCL8 expression relies in part on mRNA stabilization (20), we hypothesized that TTP, a downregulator of its mRNA half-life in glioblastoma (47) or in cystic fibrosis lung epithelial cells (3), could be absent or inactive. Hence, we analyzed different melanoma cell lines for their TTP expression. Figure 2A (left) shows that different melanoma cell lines with the V600E mutation of B-Raf express very low levels of TTP. Figure 2A (middle) also shows that the non-B-Raf-V600E melanoma cell line Rosi expresses higher basal levels of TTP. Figure 2A (middle) also shows an inverse correlation between the levels of TTP and the levels of the phosphorylated/active forms of ERK. Phosphorylated forms of ERK in Rosi cells may be seen only after overexposure of the blot. Moreover, the same inverse correlation is observed in cell extracts of primary melanocytes and cell extracts of two independent primary cultures of melanoma cells harboring theV600E mutation of B-Raf. The presence of phosphorylated forms of ERK in melanocytes is probably related to the fact that these cells were cultured in the presence of serum, fibroblast growth factor (FGF), and phorbol-12 myristate 13-acetate, three potent activators of ERK. However, phosphorylated ERK levels are higher in extracts from melanoma cells. Whereas the predicted molecular mass of TTP is 34 kDa, we observed bands of 40 to 50 kDa in melanoma cell lines, whereas multiple bands varying from 34 to 50 kDa were observed in stimulated RAW264.7 cell extracts, a well-recognized model for study of TTP and its effect on the regulation of half-life of TNF␣ mRNA (not shown) (29) . These results suggested that the bands present in melanoma cells are phosphorylated and are consistent with our previous report showing Fig. 1 . Induction of protective antitumor immunity. A: representative experiment of the inhibition of CXCL8-mediated ERK activity of CXCR2 expressing cells. Starved CXCR2 cells (C) were stimulated for 5 min with 50 ng/ml CXCL8 (C8). CXCL8 was preincubated or not in the presence of commercial anti-CXCL8 antibodies (C8 Ab), or with the serum of GST (C8 A1) or GST/CXCL8 (C8 B1) immunized mice. Actin is shown as a loading control. Mice (10 mice per group) were immunized intraperitoneally with 100 g of GST or GST/CXCL8. B: presence of CXCL1, CXCL5, and CXCL8 blocking antibodies in immunized mice was determined by the capacity of the sera of immunized mice to inhibit CXCL1-, 5-, and 8-dependent stimulation of ERK of cells expressing the CXCR2 receptor. ERK mean activity Ϯ SD obtained with the different sera is shown (Test sera). ERK activity (Control) is shown for different reference situations; in unstimulated cells (C), in CXCL1, 5-, and 8-stimulated cells (C1, C5, C8), which is considered as the 100% reference value, and in cells stimulated with CXCL8, which have been preincubated with a commercial anti-CXCL8 antibody (MAB-208, C8 ϩ Ab). ***P Ͻ 0.001. C: mice were challenged with B16F10 cells (10 6 cells) 1 wk after the third immunization. The results are expressed as the percentage of mice that developed a tumor after the indicated times. that TTP is phosphorylated by ERK in cells expressing the RAF:ER chimera stimulated by tamoxifen (13) . Moreover, treatment with calf intestine phosphatase induced a decrease in the intensity of upper bands and accumulation of faster migrating bands (see online Supplemental Fig. S3 ). We then generated A375 cells conditionally expressing a Myc-tagged form of TTP. One clone (ALT12) was specifically analyzed for its TTP expression with a homemade anti-TTP antibody, since endogenous expression was very low. Figure 2B shows a dosedependent and time course of TTP expression on tetracycline stimulation. We have shown previously that the slower-migrating bands correspond to phosphorylated bands in cells expressing the Raf:ER chimera where ERKs can be conditionally stimulated by tamoxifen (13) . Since in melanoma cells the amount of TTP was almost undetectable, we hypothesized that constitutive phosphorylation by ERK might induce TTP degradation by the proteasome, a situation already described for the MAP kinase phosphatase 3 (30) . Figure 2A , middle, and C show that the endogenous forms of TTP and particularly forms of low molecular weight are increased on inhibition of MEK by PD184352 (PD). It has to be noted that TTP levels are not much modified and somewhat decreased in Rosi cells treated by PD. Endogenous forms of TTP are also increased upon treatment with MG132 (MG) with accumulation of low and particularly high-molecular-weight forms. This result is consistent with previous results showing active degradation of TTP by the proteasome (12) . Forms of high molecular weight probably correspond to phosphorylated forms of TTP as suggested by online Supplemental Fig. S3 . Figure 2D shows that PD induced accumulation of a faster migrating form of the tetracycline-induced protein, whereas MG induced accumulation of a slower-migrating band (see dotted lane as a reference for migration). These results suggest that ERK triggers proteasome-dependent degradation of TTP in melanoma cells.
TTP destabilizes CXCL8 mRNA and reduces CXCL8 production in melanoma cells. Since activation of ERK leads to increased cell growth and angiogenesis (33, 36 ) and CXCL8 plays a major role in the etiology of melanomas (53), we investigated the relation between ERK activity and expression of CXCL8, a cytokine considered as a growth and angiogenic factor in melanomas. The online Supplemental Fig. S4A shows that incubation of A375 cells with the MEK inhibitor PD caused a rapid decrease in ERK activity and of endogenous CXCL8 mRNA levels. These changes in the amounts of CXCL8 mRNA could reflect a modification in CXCL8 transcription, as previously documented (53) , but also changes in CXCL8 mRNA stability. Supplemental Fig. S4B shows that PD184352 decreases the activity of a luciferase gene coupled to the domain of the IL-8 promoter dependent on RAS/RAF/ MEK/ERK (44) by only 30%. It suggests that contribution of ERK on transcription represents a third of the mechanisms involved in the steady-state levels of IL-8 mRNA in A375 cells.
Time-course experiments with the transcription inhibitor 5,6-dichloro-1-␤-dribofuranosylbenzimidazole (DRB) showed that the half-life of CXCL8 mRNA is superior to 6 h in A375 cells (Fig. 3A) . Thus CXCL8 mRNA appears to be a very stable mRNA. Blocking MEK activity with PD184352 reduced the CXCL8 mRNA half-life, which decreases from 6 h to 16 min in A375 cells (Fig. 3A) .
Based on our previous work (13) and data of the literature (47), we investigated whether TTP might decrease CXCL8 expression and half-life in A375 cells. We observed a tetracycline dose-dependent decrease in the mRNA half-life (t 1/2 Ͼ 3 h in untreated cells; t 1/2 ϭ 20 Ϯ 3 min for a concentration of 20 ng/ml, and t 1/2 ϭ 10 Ϯ 2 min for a concentration of 100 ng/ml). Figure 3C shows a dose-dependent decline in RNA levels that starts and is maximal at a very low concentration of tetracycline (70% reduction for 10 ng/ml), a concentration that does not induce maximal TTP expression (see Fig. 2B ). Higher concentrations of tetracycline do not further decrease CXCL-8 mRNA levels. Figure 3B shows that the CXCL8 mRNA in the presence of optimal concentrations of TTP and in the presence of DRB decreases to almost baseline levels, whereas induction of TTP alone, even after a long time (16 h of induction in Fig. 3B ), is highly efficient but not sufficient to maximally reduce CXCL8 mRNA levels. Thus the potent transcriptional effect resulting from constitutive ERK activity may compensate for the strong mRNA instability mediated by TTP. mRNA 3=-UTR are classically involved in the regulation of their stability. Therefore, we cloned the 3=-UTR of CXCL8 mRNA downstream of a minimal thymidine kinase (TK) promoter and a luciferase reporter gene (Luc). A375 cells were transiently transfected with either a TK-luciferase (TK-Luc) vector used as a negative control or TK-luciferase-CXCL8 3=-UTR (TKLuc-CXCL8) (13) . The luciferase activity obtained for the CXCL8 reporter construct in the absence of TTP was chosen as the reference value (100%). Whereas the TK-Luc construct Fig. 3 . TTP controls CXCL8 mRNA stability in melanoma cells. A: influence of ERK. mRNA decay curves of CXCL8 mRNA in A375 cells treated or not with PD184352 after addition of DRB. The mRNA half-life is indicated for each condition. *P Ͻ 0.05; ***P Ͻ 0.001. B: left, mRNA decay curves after addition of DRB at the doses of tetracycline indicated in ALT12 cells. The mRNA halflife is indicated for each condition. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. Right, ALT12 cells were incubated with the doses of tetracycline indicated. The amount of CXCL8 mRNA was quantified by qPCR. The reference value (100%) corresponds to CXCL8 relative amounts in untreated cells. ***P Ͻ 0.001. NS, nonsignificant. A375 cells were cotransfected with a TK-luciferase (TK-Luc) or a TK-luciferase-CXCL8 3=UTR (TK-Luc-CXCL8) reporter construct and different amounts of the TTP expression plasmid in the presence or absence of PD184352 (PD). C: luciferase counts obtained with the TK-Luc-CXCL8 reporter construct in the absence of TTP was taken as the value of the reference (100%). Results are reported as means Ϯ SD of three independent experiments performed in triplicate. *P Ͻ 0.05, **P Ͻ 0.01. A375 cells stably transfected with the pCDNA4/TO empty vector (A375/CONT) or ALT12 cells were incubated for 24 h in the presence of varying concentrations of tetracycline. D: amount of CXCL8 in the cell supernatant was determined by ELISA and normalized to the cell number. For each cell line the reference value (100%) corresponds to the amount of CXCL8 secreted by cells in the absence of tetracycline. **P Ͻ 0.01, ***P Ͻ 0.001. presents a basal luciferase activity that does not change following the different treatments, TTP decreases the luciferase activity generated by the TK-Luc-CXCL8 construct only at the highest concentration. Inhibition of the MEK/ERK pathway with PD184352 causes a 40% decrease in the luciferase activity generated by TK-Luc-CXCL8 (Fig. 3D) . Only high TTP concentrations combined with PD184352 further reduce the luciferase activity. These results suggest that the TTP-dependent decrease in the CXCL8 mRNA half-life relies on its 3=-UTR and that ERK might control TTP-mediated CXCL8 mRNA degradation. We next sought to determine the role of TTP on CXCL8 production using an ELISA assay (Fig. 3D) . Whereas tetracycline did not significantly modify CXCL8 expression in control A375 cells stably transfected with the pCDNA4/TO empty vector (A375/CONT), there was a significant decrease in CXCL8 expression for each tetracycline dose in TTP-expressing cells (ALT12), which reached a maximal 80% decrease for the highest tetracycline dose.
Silencing of TTP by RNA interference increases the level of endogenous CXCL8 mRNA and stimulates cell growth. To strengthen the conclusions drawn from the contribution of TTP to the regulation of CXCL8 mRNA expression, we used the RNA interference methodology. To determine the most efficient shRNA, we transfected control or two independent shRNA plasmids (named shRNA/1 and 2) targeting TTP in HEK 293 cells together with a TTP coding plasmid. HEK 293 cells were chosen for their high transfection efficiency and the absence of TTP protein (25) . Forty-eight hours after transfection, TTP expression has been analyzed by Western blotting. Figure 4A shows that whereas the control shRNA plasmid has no effect on transfected TTP, two independent shRNA downregulate TTP expression with almost 100% efficiency for shRNA/62 and 80% efficiency for shRNA/63. Two rounds of transient transfection of shRNA/1 and shRNA/1 in A375 cells downregulated the remaining endogenous TTP expression (Fig. 4B ) and subsequently increased CXCL8 expression (Fig. 4C) suggesting that the remaining endogenous TTP is still active and can still reduce CXCL8 mRNA amounts. Stable cell lines expressing control or specific shRNA were tested for their capacity to proliferate. Although A375 cells are highly proliferating cells, Fig. 4D shows that cells expressing shRNA targeting TTP grow faster than cells expressing control shRNA suggesting that TTP is a natural break in melanoma cell proliferation.
TTP overexpression reduces cell growth, induces apoptosis, and decreases autophagy. Any attempts to obtain stable melanoma cell lines expressing high amounts of TTP were unsuccessful. This suggests that melanoma cells have adapted to a threshold of TTP expression compatible with cell growth. Since melanoma cells have reduced TTP expression, we tested the consequence of reexpressing TTP on cell counts. Figure 5A shows a significant dose-dependent decrease in cell number of TTP-expressing cells versus tet-on control cells at 24 h. To determine whether TTP induces apoptosis, caspase-9 cleavage was evaluated. Figure 5B shows dose-dependent caspase-9 cleavage depending on the level of TTP expression. No cleavage was observed in the absence of tetracycline. These results suggested that tetracycline-dependent expression of TTP induces a cell death program in A375 cells. Autophagy is a major survival process (4). Recent papers suggested that RAF mutations promote autophagy, which is directly linked to melanoma tumor progression (28) . Hence, we investigated whether TTP might target mRNA coding for major factors implicated in this process to regulate cell death. BNIP3 is a BH3-only subfamily of Bcl-2 family protein that is an important mediator of autophagy (4) . Moreover, BNIP3 is upregulated in hypoxia, a condition favoring autophagy (4). Figure 5 , C and D, shows that BNIP3 is downregulated when TTP is overexpressed both at the mRNA and protein level. These results are compatible with a direct effect of TTP on BNIP3 mRNA since it contains consensus AU-rich elements targeted by TTP in its 3=-UTR (17) . When autophagy is activated, the LC3-I protein localized in the cytoplasm is cleaved, lipidated, and inserted as LC3-II into membranes of autophagosomes (48) . An increase in the amount of LC3-II and in the LC3-II-to-LC3-I ratio is a hallmark of autophagy. On the contrary, any decrease of this ratio or of the total amounts of LC3 proteins can be considered as a sign of decreased autophagy. In normoxic conditions, when TTP is induced by tetracycline, we observed a modest but reproducible decrease of the total amounts of LC3. The LC3-II-to-LC3-I ratio is slightly increased in hypoxia since the time of hypoxia is short (4). Nevertheless, Fig. 5D shows a decrease of the LC3 protein and a decrease of the LC3-II-to-LC3-I ratio in hypoxia when TTP is induced by tetracycline. Hence, TTP expression induces cell death and prevents autophagic mechanisms through, at least, downregulation of BNIP3.
The therapeutic agent sorafenib downregulates CXCL8 production through reexpression of TTP. Melanomas are chemoresistant tumors. However, ATP mimetics targeting constitutive active RAF including sorafenib have been developed. Despite poor clinical results, it appears that combination with chemotherapeutic agents is efficient in melanoma mice models (2) , which deserve clarification of the molecular mechanism of action. Hence, we investigated the effect of sorafenib on CXCL8 expression and its incidence on TTP expression. Figure 6A shows a dose-dependent decrease in CXCL8 mRNA levels following treatment with increasing doses of sorafenib, concentrations resulting in inhibition of ERK activity (Fig. 6B) . Figure 6B shows a dose-dependent increase in TTP expression following sorafenib treatment. Hence, sorafenib, in addition to its B-RAF-dependent effect on cell growth, downregulates CXCL8 through TTP increased expression.
DISCUSSION
In 2009, 68,720 patients were diagnosed with melanoma and 8,650 patients died of this disease in the Unites States (22) . Hence, it is urgent to improve the understanding of the genetic events that occur during melanoma development. Melanomas are very aggressive tumors mainly characterized by mutations of members of the ERK pathway principally N-RAS and B-RAF, where a mutation of valine to glutamate (V600E) is responsible for 80% of the mutations (10) . This mutation markedly increases the in vitro catalytic activity of B-RAF. Sorafenib, a small molecular inhibitor of wild-type B-RAF, V600E B-RAF, and C-RAF, slows the growth of melanoma xenografts (24) . More recently a mutant-specific B-RAF inhibitor PLX4032 has also demonstrated promising effects in preclinical studies (50) . However, clinical trials demonstrated, after a transient objective response, that patients subsequently A: cell number in the absence of tetracycline was considered as the reference value (100%). **P Ͻ 0.01, ***P Ͻ 0.001. B: ALT12 cells were incubated for varying times in the absence or presence of tetracycline (20 or 100 ng/ml). TTP, caspase 9 (total and cleaved forms), phospho ERK (pERK) and actin were analyzed by Western blotting. Actin is shown as a loading control. ALT12 cells were incubated in the absence or presence of tetracycline (100 ng/ml) for 24 h in normoxic (N) or hypoxic conditions (H 1%). C: BNIP3 mRNA was detected by qPCR in the different cell populations. The amounts of BNIP3 mRNA in normoxic cells are considered as the reference value (100%). The data represent the mean Ϯ SD of two independent experiments. **P Ͻ 0.01. D: ALT12 cells were incubated in the absence or presence of tetracycline (100 ng/ml) for 24 h in normoxic (N) or hypoxic conditions (H 1%). HIF-1␣, TTP, BNIP3, and the two forms of the LC3 protein (LC3-I and LC3-II) were analyzed by Western blotting. HSP90 is shown as a loading control. The mean Ϯ SD of the LC3-II/ LC3-I ratio is shown. *P Ͻ 0.05.
progressed with a median duration of response to sorafenib (18) or PLX4032 (15) of a few months. The disappointing clinical results raised the question of whether mutant B-RAF was the best therapeutic target and also whether new markers of tumor aggressiveness downstream of B-RAF need to be discovered. The fact that 80% of benign nevi present with the V600E mutation (39) and that expression of the B-RAF V600E mutation alone failed to fully transform melanocytes favors this point of view (9) . The need of potent prophylactic prevention of melanoma for risk populations is also a very important goal particularly for melanoma dependent on prolonged exposure to sunlight. Improvement of the early diagnosis and the stratification of patients with local tumors, which require aggressive intervention, are also of particular importance for future therapeutic intervention. Our study strongly suggests that activation of the ERK pathway constitutes a molecular node for downstream events controlling melanoma development. In particular, CXCL8 constitutes an important autocrine growth factor that stimulates the ERK pathway through the G protein-coupled receptors CXCR1 and CXCR2 (16) . Hence, an elevated ERK activity is maintained in two independent ways resulting in addiction of melanoma cells. Since targeting upstream events at the level of RAS, RAF, or the PI3 kinase pathway [stimulated by constitutive active N-RAS (32)] was not successful, our study shows that targeting downstream events of these pathways represents an alternative therapeutic strategy. Moreover, we identified TTP as an important mediator of CXCL8 production in melanoma cells as in others tumors [glioblastomas (47) , breast, and cervical cancers (1, 7) ]. Since TTP is phosphorylated by ERK (8) and AKT (31) , it might represent another independent prognostic factor, which integrates signals from the RAS/RAF/MEK/ERK and PI3 kinase pathways. Our results show that the constitutive ERK activity mediated by the V600E B-RAF mutation targets TTP to the proteasome. This result is somewhat discrepant with the fact that ERK activation is important for TTP induction at the mRNA and protein level in normal fibroblasts (13) . Since constitutive TTP expression might be toxic, normal cells eliminate TTP expression after long-term activation by the proteasome but also through destabilization of its own mRNA (49) . Melanoma cell lines have probably diverted this physiological mechanism to maintain low endogenous levels of TTP. Our results on melanoma cells show that TTP reduces the activity of a CXCL8/3=UTR reporter construct. However, the TTP concentration needed to reduce luciferase activity is higher than in nontumoral HEK 293 cells. Moreover, full inhibition of the luciferase activity necessitates inactivation of ERK by MEK inhibitors. This suggests that the slower-migrating forms of TTP are phosphorylated by ERK and are less active. As for TNF-␣ mRNA degradation, phosphorylation creates a 14-3-3 binding site that may sequester TTP away from the cytoplasmic stress granules and inhibits TTP-dependent degradation of CXCL8 mRNA (46) . Different proteins compete for binding to ARE to stabilize or to induce mRNA degradation. Among the stabilizing proteins, HuR might be responsible for the increase in the CXCL8 mRNA half-life since this partnership has already been demonstrated in glioma (47) and also because HuR is abundant in the different melanoma cell lines that we have tested. Downregulation of CXCL8 mRNA upon TTP overexpression suggests a competitive process of binding between TTP and HuR.
MEK inhibitors reduce cell growth and induce apoptosis of melanoma cells (41) . TTP expression is also sufficient to induce apoptosis more rapidly than in NIH3T3 cells where cell death was observed 48 h after TTP transfection (23) . Suppression of the autocrine growth/survival loop dependent on CXCL8 production is probably implicated in TTP-dependent induction of apoptosis. However, TTP may also downregulate other ARE-containing mRNA coding for proteins implicated in cell growth and survival. Among them, cyclin D is probably a good candidate since it is indispensable for G0/G1 transition (27) and its mRNA is a target of TTP (31) .
The anti-proliferative, pro-apoptosis, anti-autophagic, and anti-angiogenic role of TTP might represent a potent antitumor therapy. A recent study by Planel et al. (38) demonstrated that injection of a TTP-related protein fused to HIV-derived TAT protein transduction domains had a strong antitumor effect on xenografted tumors in nude mice. These promising results putatively open up a new avenue for tumor treatment. Knowing the potent in vitro effect of TTP we speculate on a strong action on melanoma growth.
